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Abstract Charcot-Marie-Tooth (CMT) disease is a clini-
cally and genetically heterogeneous disorder. All mendelian
patterns of inheritance have been described. We identified a
homozygous p.A335V mutation in the MED25 gene in an
extended Costa Rican family with autosomal recessively
inherited Charcot-Marie-Tooth neuropathy linked to the
CMT2B2 locus in chromosome 19q13.3. MED25, also
known as ARC92 and ACID1, is a subunit of the human
activator-recruited cofactor (ARC), a family of large
transcriptional coactivator complexes related to the yeast
Mediator. MED25 was identified by virtue of functional
association with the activator domains of multiple cellular
and viral transcriptional activators. Its exact physiological
function in transcriptional regulation remains obscure. The
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77030, USACMT2B2-associated missense amino acid substitution p.
A335V is located in a proline-rich region with high affinity
for SH3 domains of the Abelson type. The mutation causes
a decrease in binding specificity leading to the recognition
of a broader range of SH3 domain proteins. Furthermore,
Med25 is coordinately expressed with Pmp22 gene dosage
and expression in transgenic mice and rats. These results
suggest a potential role of this protein in the molecular
etiology of CMT2B2 and suggest a potential, more general
role of MED25 in gene dosage sensitive peripheral neuro-
pathy pathogenesis.
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Introduction
Charcot-Marie-Tooth disease (CMT) or hereditary motor
and sensory neuropathy (HMSN) represents a group of
frequent, clinically and genetically heterogenous disorders
of peripheral nerves [1–3]. Two major CMT forms are
distinguished by electrophysiological criteria: the demye-
linating CMT (HMSN) type 1 and the axonal CMT type 2
[3]. Autosomal dominant CMT type 1 is most frequently
caused by a 1.4-Mb tandem duplication including the
PMP22 gene (CMT1A [MIM #118220]) [4, 5]. For the
dominantly inherited axonal CMT type 2A mutations in
the Mitofusin 2 gene (MFN2 [MIM *608507]) [6] are the
most frequently observed variations. Intermediate types of
CMT have also been described [7, 8]. To create animal
models of the most frequently observed form of CMT,
CMT1A, transgenic mice and rats that carry altered copy
numbers of the PMP22 gene have been generated [9–11].
These animals recapitulate many pathological hallmarks of
the human disease [12].
Both the autosomal recessive demyelinating (CMT4
[MIM #214400]) and the autosomal recessive axonal forms
(ARCMT2 [MIM #605588, %605589]) are less frequently
observed. For the autosomal recessive axonal ARCMT2,
the first locus was mapped on chromosome 1q21.2–q21.3
[13]. Subsequently, De Sandre-Giovannoli et al. identified a
homozygous R298C mutation in the LMNA gene in three
consanguineous Algerian families with severe and early
onset [14]. Furthermore, mutations in the ganglioside-
induced differentiation-associated protein 1 (GDAP1) gene
on chromosome 8q21.1 have been identified in three
families of Spanish ancestry with ARCMT2 [15]. These
patients were characterized by childhood onset, distal
muscle weakness, sensory deficits, and vocal chord paresis
in some of the patients [16].
We investigated an extended Costa Rican family (CR-P)
with Spanish and Amerindian ancestors that segregated an
autosomal recessive CMT type 2 neuropathy that mapped to
chromosome 19q13.3 (ARCMT2 [MIM %605589]) [17, 18].
Here we provide genetic and functional data to support
the contention that the homozygous p.A335V mutation in
the gene for Mediator 25 (MED25) is responsible for the
neuropathy segregating in the family CR-P from Costa Rica.
Materials and methods
Patients
The clinical and electrophysiological investigations took
place in the city hospital of Palmares in Costa Rica, 31
family members underwent genetic analysis; clinical and
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276 Neurogenetics (2009) 10:275–287electrophysiological evaluations were performed on 11
subjects. Eight of these studied subjects—three males and
five females—were clinically diagnosed with motor and
sensory neuropathy. Informed consent was obtained from all
study participants. The age at onset of the chronic symmetric
sensory-motor neuropathy was 28 to 42 years (mean 33.8±
5.3), the electrophysiologic data reflected a primary axonal
degenerative process with mild myelin impairment in the
course of the disease [18]. The electrophysiological inves-
tigations were described in detail elsewhere [18].
Genetic analysis
Genomic DNA was extracted from peripheral blood
samples by the salting-out method. DNA was diluted in
HPLC–H20 to a concentration of approximately 50 ng/ml
and stored at 4°C. The critical interval in chromosome
19q13.3 could be refined to 1 Mb between marker
D19S604 and a SNP (c.901 T>C) identified in the nuclear
receptor subfamily 1, group H, member 2 (NR1H2) gene by
homozygosity mapping.
Primers flanking all exons of 53 genes corresponding to
487 amplicons in the critical interval were designed using
the Primer3 program. All 19 exons of MED25 have also
been sequenced. Oligonucleotide sequences and PCR
conditions are available on request. Bidirectional direct
sequencing was implemented using the BigDye Terminator
Cycle Sequencing Kit (Applied Biosystems) on an ABI
3730 capillary sequencer (Applied Biosystems) for all
variations found with unidirectional sequencing. Sequence
traces were evaluated using the DNAStar software package.
A BAC-contig on the critical interval was constructed
using public databases and confirmed with Celera scaffolds.
This interval, included on the public contig NT_011109
and the Celera-Scaffold GA_x2KMHMQE7RG (Celera
Publication Site) of chromosome 19q, was analysed with
several programs including NIX (http://www.hgmp.mrc.ac.
uk/Registered/Webapp/nix/) and GrailEXP (http://compbio.
ornl.gov/grailexp/). All genomic sequences included in the
critical interval were also compared with the GenBank data-
base of the National Institutes of Health of USA. (www.ncbi.
nlh.gov/), using the simple-BLAST program against the “nr”
database, for finding homologous sequences and expressed
s e q u e n c e dt a g s( E S T s )t h a tc o r r e s p o n dt ot h er e s p e c t i v eg e n e .
To identify the most related protein sequences with
MED25, ”BLAST” and ”Advanced BLAST2 & Orthologue”
(http://dove.embl-heidelberg.de/Blast2e/) programs were
used. For selection of candidate genes, we also used the
Build 35 of the public human genome assembly at UCSC.
The UCSC map provided known proteins and genes as
curated by SWISS-PROT and NCBI RefSeq project, aligned
mRNAs and ESTs, Ensembl gene builds, Genscan and
FGENESH gene predictions, and alignments of other
genomes by similarity. Expression of candidate genes and
anonymous transcripts in nervous system, and especially in
spinal cord and peripheral nerve, was checked by querying
public data repositories for EST matches and serial analysis
of gene expression (SAGE) tags. Expression of candidates
was also tested by RT-PCR.
Globular regions and elements of secondary structure in
MED25 were predicted using the servers Globplot2.3
(http://globplot.embl.de/) and PsiPred (http://bioinf.cs.ucl.
ac.uk/psipred/) with standard settings.
Fluorescence spectroscopy and calculation of the binding
constant
All fluorescence spectra were measured in a F-4500
fluorescence spectrophotometer (Hitachi, Tokyo, Japan)
at an excitation wavelength of 280 nm and an emission
wavelength of 340 nm at 294 K. A semi-micro quartz
fluorescence cell (light path 10×4 mm) with magnetic
stirrer was used. To obtain the titration curves for
calculation of the binding constants (Kd), synthetic
peptides according to the MED25 wildtype (Ac-
QLPPGPPGAPKPPPAS-CONH2) and the Ala335Val
mutation (Ac-QLPPGPPGVPKPPPAS-CONH2)w e r ep u r -
chased from Jerini (Berlin, Germany). Stock solutions of
up to 5 mM were added in small increments to samples
containing 0.5 µM SH3 domains in 50 mM Tris/HCl,
150 mM NaCl, pH 7.4 Samples were stirred for 2 min,
fluorescence was recorded for 30 s and averaged. Ligand
binding was monitored by detecting the changes of
intrinsic fluorescence for a tryptophane residue located in
the binding site of the SH3 domains. Since the concentra-
tion of the SH3 domain protein was low compared to the
peptide concentration, the experimental data were fitted to
the standard equation [19]
F ¼
Fmax   peptide ½ 
Kd þ peptide ½ 
where [peptide] gives the final peptide concentration at each
measurement point, F is the measured protein fluorescence
intensity at the particular peptide concentration, and Fmax is
the observed maximal fluorescence intensity of the protein
when saturated with the peptide. Nonlinear regression curve
fitting was carried out to fit the experimental data to the
equation, with Fmax and Kd as fitted parameters. The change
in protein concentration that occurred as a result of peptide
addition was properly corrected.
Molecular modelling
Models of the complexes of wild-type and mutant MED25
with Abl and Lck were generated by homology modelling
Neurogenetics (2009) 10:275–287 277using previously published complexes of the respective SH3
domains with proline-rich ligands as templates [20, 21].
Proper alignment of the ligand sequences in complex with
the SH3 domains was derived using the iSPOT server [22].
Models were generated using SwissModel [23]a n dt h e
quality was verified by PROCHECK [24]a n dW H A T _
CHECK [25] analyses. Visualization of the structures was
performed using MolMol [26] and DS Viewer (Accelrys Inc.).
Transcription activation
Plasmid hARC92/ACID1 expression vectors were con-
structed by cloning of PCR products in the multiple
cloning site of a previously modified pCIneo Vector
(Promega), which contains a GAL4 DNA-binding
domain (amino acids 1–147) fused to a Myc epitope
positioned between the NheI and the EcoRI sites.
ARC92/ACID1 derivatives correspond to the human
factor. QuikChange site directed mutagenesis kit (Stra-
tagene) was used to generate the A335V mutants. All
clones were verified by sequencing. The GAL4 reporter
pGLMRG5 is derived from pMRG5 [27] but contains a
luciferase gene instead of a G-free cassette. Jurkat T cells
(plasmid amounts refer to 1.0×10
7 cells) were transfected
by electroporation with 10 µg of pGLMRG5 reporter and
increasing amounts of GAL4-fused constructs. Total
Fig. 1 Pedigree of the CR-P
family that carries the CMT2B2
mutation. Colored lines (red,
green, black) were used to
visualize the relationship within
family CR-P. The redefined
critical interval of 1 Mb between
D19S604 and the c.901C>T
SNP in NR1H2 is indicated (a).
Sequence analysis of MED25
revealed the homozygous
mutation A335V (b)
278 Neurogenetics (2009) 10:275–287amounts of DNA (20 µg) were adjusted by supplemen-
tation with the respective empty expression vectors. A ß-
Gal expression vector was co-transfected in order to
normalize luciferase levels.
Animals
Wild-type, trembler, and transgenic mice
Transgenic Pmp22
tg and Pmp22
−/− mice have been
described [28, 29]. For quantitative and RT-PCR analysis,
RNA derived from sciatic nerves of four animals has been
pooled. RNA was extracted with Trizol (Invitrogen),
according to manufacturer’s recommendations, from rat
sciatic nerve at the indicated developmental time points
and adult tissues. Nerve cut and crush experiments were
performed in strain C57/Bl6 mice 2 [30]. For each time
point, the nerves of three animals were pooled, the
contralateral site was used as control. Quantitative RT-
PCR was carried out on an ABI Prism 7000 Sequence
Detection System using TaqMan technology (Applied
Biosystems). PCR was performed with the unlabelled
primers 047Qfor (5′-CTCCGCAAGCACTACCTGCT-3′)
and 047Qref (5′-CCCAAAGTCCGTCTCTGCA-3′) and the
5′ FAM labelled primer 047QP (5′-CCATAGAGTACTT
CAACGGG-3′). The reactions were carried out in triplicate
using TaqMan Universal PCR Master Mix was according to
the manufacturer′s recommendations. The amount of 18S
rRNA was determined in parallel reactions as an internal
control.
Transgenic rats
Pmp22
++/+ rats have been described [28]. RNA was
derived from sciatic nerve sections and analysed via RT-
PCR and quantitative PCR for Pmp22 and Med25
expression. Progesterone and onapristone supplementa-
tion and also the behavior tests using the bar holding
time as phenotypic indicator were as described, proges-
terone diet was at 20 mg/kg [31]. RNA was extracted
from rat sciatic nerve with Trizol (Invitrogen) according
to manufacturer’s recommendations. Quantitative RT-
PCR was carried out on an ABI Prism 7000 Sequence
Detection System using TaqMan technology (Applied
Biosystems). PCR was performed with the unlabelled
primers 047Qfor (5′-CTCCGCAAGCACTACCT
GCT-3′) and rat_047_Qrev (5′-CCCAAAGTCC
GTCTCTGCG-3′)a n dt h e5 ′ FAM labelled primer
rat_047_QP (5′-CCATAGAGTACTTCAACGGA-3′).
The reactions were performed in triplicate using TaqMan
as described above with mice. Additionally the experi-
ments have been replicated using GAPDH as an internal
control.
Results
Identification of the neuropathy causing homozygous
MED25 mutation p.A335V
Family CR-P originates from a single town in the province
of Alajuela, Republic of Costa Rica in Central America. This
family is genealogically related and the affected members are
descendants of consanguineous matings (Fig. 1a). The
critical interval in chromosome 19q13.3 could be refined to
1 Mb between marker D19S604 and a SNP (c.901 T>C)
identified in the nuclear receptor subfamily 1, group H,
member 2 (NR1H2)g e n e( F i g .1a). This refinement could be
done since individual B-5.3 [17] agreed with his participa-
tion on this study.
To identify the disease causing allele DNA sequence
analysis of the entire critical region was implemented.
Overall, 53 genes corresponding to 487 amplicons were
analysed. Three genes, Pronapsin A (NAPSA), MED25 and
the prostate tumor overexpressed gene 1 (PTOV1) showed
variations (A310T, A335V, and I252V, respectively) that
cosegregated with the recessive neuropathy trait in family
CR-P. A p.A335V missense amino acid substitution in
MED25 appeared to be the disease causing variation for
CMT2B2 based on the following observations (Fig. 1b).
The alanine at position 335 is evolutionarily conserved,
indicating a biological function suggested also by its central
position in a proline-rich motif (Fig. 2a). The population
carrier frequency (0.68 %; allele frequency, 0.34 %) is
below that usually observed for a polymorphism and in
accordance with autosomal recessive inheritance (Table 1).
The incidence of 1:88,000 (Hardy–Weinberg, q
2=1.1391
−5)
is concordant with other recessive types of CMT [2]. We
analyzed 2,064 chromosomes of Central American, Euro-
pean, and US American ancestry and found seven hetero-
zygous p.A335V carriers; five were healthy controls from
Costa Rica (632 Costa Rican controls analyzed), one was a
healthy control from Germany (23 German controls
analyzed), and one was a female CMT1 patient with
unknown genetic defect from Germany (377 patients
analyzed). Based on these data the incidence in Costa Rica
is 1:66,358 (Hardy–Weinberg, q
2=1.13914
−5) at a popula-
tion carrier frequency of 0.76%, combined for the USA and
Germany in 1:154,449 (Hardy–Weinberg, q
2=6.4746
−6). In
contrast, the p.A310T variation in NAPSAwas observed at a
population frequency of 5% (251 control chromosomes
tested) consistent with a common polymorphism. The p.
I252V (c.754 A>G) variation in PTOV1 was found
homozygous in a healthy control, thus likely excluding
PTOV1 as a candidate gene. Neither the p.A310T nor the p.
I252V fall within conserved amino acids.
Another 98 variations comprising translationally silent
changes, splice site variants and 13 amino acid substitutions
Neurogenetics (2009) 10:275–287 279were identified, but could be excluded as causes of the
axonal neuropathy mostly due to the existence of homozy-
gous healthy carriers. The p.A335V mutation in MED25 is
the only variation in the critical interval in 19q13.3 that
fulfills all formal genetic criteria to be the disease causing
variation for CMT2B2. We performed further experiments
in order to assign a biological function to this region of
MED25 and characterize the effects of this mutation.
Functional properties of the MED25 p.A335V mutation
The p.A335V mutation resides in a proline-rich region
(Fig. 2a,b). This region was predicted to be a potential SH3
ligand by iSPOT (http://cbm.bio.uniroma2.it/ispot/)[ 22].
According to these predictions, the wildtype should
represent an interaction partner of the SH3 domain of the
Abelson tyrosine kinase family (AblSH3). The mutant
MED25 may retain this affinity but is furthermore predicted
to have a strong affinity for the SH3 domains of the Src-
family of kinases. Thus, the mutant MED25 should bind a
broader variety of SH3 groups.
To test this hypothesis, fluorescence binding experi-
ments were performed using the SH3 domains from Abl
(clone pET3d, a kind gift of Luis Serrano [32]) and from
the Src-family kinase Lck [21]( F i g .3a,b). Computational
investigations of MED25 predict that the SH3 binding
region is nonglobular and lacks any regular secondary
structure. Therefore, synthetic MED25 peptides are
expected to adequately reflect the binding properties of
full-length MED25 Therefore, synthetic MED25 peptides
that cover the binding site were used for the titration
experiments.
Whereas the affinity of synthetic MED25 peptides for
Abl is almost unaltered by the mutation (Kd(wt)=2.37±
0.93 µM; Kd(mutant)=2.91±0.66 µM), the mutant binds
one order of magnitude stronger to the Lck SH3 domain than
wild-type MED25 (Kd(wt)=33.47±15.01 µM; Kd(mutant)=
5.38±1.05 µM).
Fig. 2 Conservation of the
amino acid alanine in position
335 (a) and the SH3-binding
motif in MED25 (b). Genomic
structure, domains, and peptide
motifs present in MED25. The
von Willebrandt factor type A
(vWA) domain and an activator-
interacting domain (ACID) were
previously verified experimen-
tally [35, 36]. The SH3-binding
site result from a computational
prediction and its SH3-binding
ability has been proven in the
present study
Table 1 Frequency of the A335V mutation in controls and other
neuropathy patients
Healthy
controls
Neuropathy patients
without known mutation
Total
Individuals 655 377 1,032
Ala335Val carrier 6 1 7
The A335V mutation was analyzed via restriction analysis of PCR
products of exon 9 using the enzyme HgaI and subsequent sequence
analysis for confirmation. For the neuropathy patients without known
mutation all coding exons of MED25 have been sequenced
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affinity shows that the A335V mutant binds to AblSH3 and
LckSH3 with a very similar affinity, while wild-type MED25
binds significantly stronger to Abl than to Lck. Thus, the
increase in affinity for Lck observed in the mutant leads to a
loss of binding specificity for Abelson SH3 domain.
To rationalize the effects of the mutation on its binding
properties,wemodelledthestructureofthecomplexesformed
by MED25 and the Abl or Lck SH3 domains (Fig. 3c). In the
MED25–AblSH3 complex (Fig. 3c, top panel) residue 335 is
oriented away from the SH3 domain explaining why the
alanine to valine mutation does not affect affinity. In the
MED25–LckSH3 complex (Fig. 3c, lower panel), Val335
packs into a hydrophobic pocket of the LckSH3 surface. The
respective contacts cannot be formed by the shorter sidechain
of wild-type alanine potentially explaining the observed
increased affinity of the mutant. Src-family kinases generally
exhibit a binding preference for ligands with long aliphatic
sidechains at the respective sequence position [33, 34]. Thus,
it can be anticipated that the mutation in MED25 may
increase the affinity for a broad range of members of this
family which will block the binding site and in effect may
decrease the dosage of free mutant MED25 protein com-
pared to the wildtype because of this sequestration.
To further investigate the in vivo function of this proline-
rich motif as part of the Mediator complex within RNA
polymerase II, clones comprising the protein coding region
of the MED25 p.A335V mutation were tested for transcrip-
tional activation. The mutation has been analyzed in the
context of a GAL4 fusion protein using a transient reporter
assay. GAL4-MED25 proteins have previously been shown
to activate transcription that correlated with recruitment of a
functional Mediator complex [35]. In this assay, the p.
A335V mutation has little influence on transcription
activation (Fig. 4). As expected from the previous charac-
terization of the Mediator binding domain located in the N-
terminal domain (NTD, aa 1–226) wild-type and mutant
proteins bound indistinguishably to Mediator upon trans-
fection into HeLa cells. Thus, a more significant influence
of the mutation on specific genes may be possible.
In summary, the p.A335V mutation results in an
interaction with an extended range of SH3 domains. We
hypothesized that this may affect the specificity and degree
of activation of the downstream target genes in the
peripheral nervous system (PNS).
Fig. 3 Affinity test results for MED25 binding to Abl SH3 (a) and
Lck SH3 (b). Fluorescence titration experiments were performed for
wild-type (filled square, dotted line) and mutant MED25 peptides
carrying an A335V point mutation (filled circle, solid line). Curves
were fitted according to the equation given in methods. c Models of
MED25 in complex with Abl SH3 (top) and Lck SH3 (bottom)
visualizing the effect of the A335V mutation. The SH3 domains are
shown in space-filled representation and the acidic and basic surface
patches are colored in red and blue, respectively. White surface
patches correspond to nonpolar regions. The MED25 binding region is
shown as tube and residue 335 is shown in stick presentation

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The findings described above suggest that the p.A335V
mutation in MED25 causes CMT2B2 by a "loss-of-
specific-function". A quantitative RT-PCR expression anal-
ysis for Med25 using RNA derived from several tissues of
adult rats was performed to establish a highly differentiated
gene expression profile. This analysis revealed an ubiqui-
tous expression of Med25 (Fig. 5a) confirming and
extending previous Northern blot studies [35, 36] to dorsal
root ganglia and sciatic nerve, tissues affected in peripheral
neuropathies. The highest expression levels were found in
dorsal root ganglia, cerebellum, cortex, and optic nerve
indicating an important function in the nervous system,
whereas the lowest expression was in the skin.
An analysis reflecting the time course of sciatic nerve
development and maintenance in rat-derived tissue revealed
a relatively constant expression from day 1 to day 20 after
birth for Med25 compared to Pmp22. However, at day 120
an approximately 50% reduction was found for Med25
(Fig. 5b).
Med25 expression in Pmp22-transgenic mice and rats
The CR-P patients were diagnosed as having primary
axonal peripheral neuropathy; however, a mild myelin
impairment in the late disease course indicated by slightly
reduced nerve conduction velocities was also observed
[18]. This points to complex effects on the peripheral
nervous system. On the other hand, axonal damage is also a
consequence of prolonged loss of glial support observed for
most demyelinating neuropathies including CMT1A [37,
38]. We hypothesized that MED25 may represent a
transcription activator with a certain role for both types of
peripheral neuropathies. The currently best characterized
animal models for demyelinating peripheral neuropathies
are transgenic mice and rats with altered Pmp22 gene
dosage. Mice with increased or reduced copy numbers of
Pmp22, or altered transcription levels of Pmp22 using a tet
promotor [39], develop a demyelinating as well as a
pronounced distal axonopathy that correlates with the
clinical progression of the respective disease [40–42]. Thus,
it was of basic interest to investigate if Med25 might be
involved in transcriptional regulation of Pmp22. We
performed quantitative expression analysis of Med25 in
sciatic nerve extracts derived from mice carrying either the
Trembler (Tr) point mutation in Pmp22 [43], a null mutant
(Pmp22
−/−)[ 29] and overexpressing mutants (Pmp22
tg,
[28]. The respective phenotypes resemble DSN, hereditary
neuropathy with liability to pressure palsies (HNPP,
Pmp22
−/−), or CMT1A. Surprisingly, Med25 was coordi-
nately expressed with Pmp22 gene dosage and expression
in Pmp22
−/− and Pmp22
tg transgenic mice (Fig. 6a). High
Pmp22 transcript levels are associated with high Med25
levels and a reduced Pmp22 expression with a low Med25
expression compared to wildtype. In contrast, the Pmp22
Tr
mutation had almost no effect on Med25 expression. This
Fig. 5 Expression profile and refined expression analysis for Med25.
RNA extracts derived from rat tissue have been analyzed via qRTPCR
(a). An ubiquitous expression was demonstrated, for peripheral nerves
the expression in DRG and sciatic nerve is shown. The time course of
Med25 expression during developing sciatic nerve of rats is constant
till day 20, but reduced late in development at day 120 (b). In
comparison, Pmp22 expression represents a typical time course of
myelination
Fig. 4 Transcription activation-Gal4 reporter assay using full-length
clones (1–754) for the wild-type (filled square) and A335V (filled
diamond) mutation at different protein concentrations. The highest
activation at 5 µg was found for a Gal-(1–715) clone (filled triangle,
left side top). The empty vector pGLMRG5 was used as control (filled
circle, left side down)
282 Neurogenetics (2009) 10:275–287may indicate a different molecular pathology for point
mutations in Pmp22 compared to the gene dosage related
peripheral nerve disorders [44]. For further confirmation of
this result, we analyzed Med25 expression in a second
animal model, transgenic rats carrying three to five Pmp22
copies [28]. Almost identical to the results in Pmp22
tg
mice, the Med25 expression correlated also with the
increased Pmp22 dosage and expression (Figs. 6b and 7a).
Thus, the correlation of Med25 and Pmp22 expression was
observed in independent animal models.
The effects of progesterone and a progesterone-
antagonist, onapristone, on epigenetic modification of
Pmp22 expression in peripheral nerves of Pmp22 transgenic
Fig. 7 Correlation of Pmp22 and Med25 in expression and behavior
of CMT rats. A significant correlation of Pmp22 and Med25
expression in sciatic nerve extracts was found by qRTPCR analysis
of 32 animals (12 onapristone-, 8 placebo-, and 12 progesterone-
treated (a). A significant correlation of holding time on the bar and
Med25 expression was found, high Med25 expression results in short
bar holding time. Low Med25 expression results in an extended bar
holding time (b)
Fig. 6 Med25 qRTPCR expression analysis in Pmp22 transgenic
animals. Wild-type and trembler mice showed similar Med25
expression, whereas Pmp22
tg mice showed an increased and
Pmp22
−/− mice a reduced expression (a). CMT (Pmp22
++/+) rats
revealed also a significantly increased expression compared to
wildtype (b). After progesterone supplementation, similar significant
results were obtained, whereas onapristone had no significant effect
(c). Med25 dosage is strictly correlated with Pmp22 dosage in
Pmp22
−/− and Pmp22
tg mice and Pmp22
++/+ rats (n=number of
animals examined)
Neurogenetics (2009) 10:275–287 283rats were reported recently [31]. Progesterone increases
Pmp22 expression and the progesterone antagonist de-
creases its expression accompanied by improvement of the
phenotype in rats. The correlation of Med25 dosage with
Pmp22 dosage in peripheral nerves of transgenic animals
was an intriguing finding that stimulated us to perform
additional experiments with regard to progesterone and
onapristone treatment of these transgenic rats. Comparable
to the observation for Myelin Protein Zero (MPZ, P0)
expression, progesterone-treated (20 mg/kg) male rats
revealed a further increase of the Med25 expression
(Fig. 6c). However, onapristone treatment had no signifi-
cant reducing effect (Fig. 6c). This may indicate that
Med25 expression is not regulated directly by the proges-
terone receptor but is linked via an unknown pathway to
Pmp22 dosage and expression.
Med25 expression was also correlated with the behav-
ioral phenotype of these animals measured in the bar
holding test [28, 31]. Med25 and Pmp22 transcript levels
vary in a wide range in these Pmp22
++/+ CMT rats
(Fig. 7a). The Pmp22
++/+ (progesterone-treated) rats at
age of 5 weeks with relatively low Med25 expression
showed an increased bar holding time, whereas the animals
with high Med25 expression had a short time on the bar
(Fig. 7b).
Med25 expression and nerve injury
We have further investigated Med25 and Pmp22 expression
after injury to peripheral nerves using qRT-PCR analysis.
After permanent sciatic nerve transsection, without allow-
ing nerve regeneration, Pmp22 transcript levels were
strongly reduced while Med25 expression was only
moderately decreased (Fig. 8a). If a crush injury was
applied, similar results were obtained 12 days after lesion
(Fig. 8b). Sixty days after crush lesion, when nerve fibers
have mostly regenerated and remyelinated, Pmp22 levels
are almost back to controls of unlesioned nerves while
Med25 levels have only partially recovered. We conclude
that both Med25 and Pmp22 expression are regulated by
neuron–Schwann cell interactions in lesioned peripheral
nerves although this phenomenon is more pronounced for
Pmp22.
Discussion
We identified a missense mutation p.A335V in a yet
unassigned transcription activation domain of MED25
cosegregating with a peripheral neuropathy in a Costa
Rican kindred. Heterozygous p.A335V was found in five
out of 632 healthy Costa Rican controls and furthermore in
one German healthy control supporting the recessive nature
of this mutation. These observations suggest that A335V is
not a private mutation, but a very rare variant, until now,
only in homozygous state in CMT2B2 patients [15, 45].
The incidence for CMT in Costa Rica is 1:66,358 (Hardy–
Weinberg, q
2=1.507
−5), whereas that combined for the
USA and Germany is 1:154,449 (Hardy–Weinberg, q
2=
6.4746
−6). The difference may be explained by a potential
founder effect for the p.A335V MED25 mutation due to the
Spanish ancestry of immigrants in the sixteenth century of
the extended Costa Rican family. Interestingly, for a
recessive GDAP1 mutation (p.Q163X) a similar common
haplotype shared by nonrelated patients and families with
Spanish origin was described [46, 47].
Fig. 8 Med25 and PMP22 expression levels analyzed by qRTPCR
after sciatic nerve transsection (a) or crush injury (b). Transcript levels
are given as percentage of control (unlesioned) nerves, 12 days or
60 days after lesions
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public databases (rs34889830 and rs4290565), nevertheless
these polymorphisms were not found in additional ESTs or
genomic sequences in databases and were not observed in
the 377 neuropathy patients via sequence analysis. For
MED25 several splice variants are known, especially for the
3′ region [35, 36, 48]. One of them is the P78 cDNA
expressed in prostate cancer cells [48]. Some conserved
domains, among them the von Willebrandt factor type A
(vWA) domain- and Synapsin-related regions, were
assigned according to homology data [35, 36]. An
interaction with Mediator of the vWA domain was recently
shown by immunoprecipitation [35, 36]. It was also shown
that MED25 contains an activator-interacting domain
(ACID) which is a functionally important target of the
VP16 transcriptional activator [35, 36]. The MED25 VP16-
binding domain was later assigned to a discrete region
between amino acids 402 and 590 [35, 36].
We describe the proline-rich SH3 recognition motif
comprising the p.A335V mutation. Affinity experiments
using synthetic MED25 peptides showed a loss of binding
specificity of the mutant as shown for the interaction with
the Abl and Lck SH3 domains (Fig. 3). Although both
types of kinases have been associated with the nervous
system [49, 50], their interconnection with transcription
activation as suggested by the MED25 mutation in family
CR-P has not yet been shown. This raises the question
whether additional cofactors, mediated by their SH3
domains, might act as interaction partners of MED25 in
the nervous system. At present, 839 different human SH3
domains [51] of mostly uncharacterized binding preferences
are known, which renders the existence of additional MED25
interaction partners feasible. Based on the extension of
affinity to a broader range of SH3 domains detected for the
MED25 mutant, however, we anticipate that the number of
binding partners will be larger for the mutant than for the
wildtype. Such interactions include an increased number of
nonphysiological interactions and a concomitant "loss-of-
specific-function". As a further consequence, the MED25
physiological function will be reduced in a dose-dependent
manner by increased competitive binding to additional
interaction partners. This situation could be compared to
recessively inherited deletions, e. g. spinal muscular atrophy
with two distinct survival motor neuron genes responsible
for the resulting phenotype.
The wild-type and mutated proline-rich motif in MED25
revealed in our study an intrinsic transcription activation
property in a GAL4 reporter assay indicating a novel in
vivo function. The "loss-of-specific-function" induced by
the A335V mutation may activate gene transcription in
peripheral nerves with remarkably reduced degree and
specificity for the cognate downstream target genes. The
reduced, but maintained wildtype function may potentially
explain a mild peripheral neuropathy with late age of onset
(mean 33.8 years) in an autosomal recessive trait.
The significant correlation of Med25 and Pmp22 dosage
and disease phenotype in transgenic animals was also present
in preliminary siRNA knockdown experiments (data not
shown). This raises the question of how a structural
membrane protein can influence the expression of a
transcription activator in a yet unknown signal transduction
pathway [9]. EGR2, a transcription factor associated with
CMT1A, DSN, and CHN, plays an essential role during
peripheral nerve myelination and differentiation of Schwann
cells [52]. The recessive p.I268N mutation abrogates the
binding of NAB repressors and causes, in homozygous state,
a severe phenotype (CHN). This finding may reflect a
threshold effect in which certain increased protein level of
the downstream PNS target gene(s), e. g. PMP22 and P0,
must be achieved for manifestation of phenotype [53, 54]. In
Tr mice abnormal retention within the endoplasmic reticulum
of myelinating Schwann cells was described earlier [55].
However, the pathway from increased PMP22 dosage to
myelin impairment and axonal damage remains enigmatic.
Furthermore, the PNS target genes regulated by MED25 are
currently completely unknown.
The p.A335V mutation was identified in patients
presenting with an axonally classical peripheral neuropathy
accompanied by mild myelin impairment. With regard to
our expression analysis results for MED25 in sciatic nerves
of transgenic animals and after injury a primary, subtle
molecular lesion in the CR-P patients could be occurring in
Schwann cells. The pathway from Schwann cell defect to
axonal damage is unknown. MED25 is expressed in
reasonable amounts in the cerebellum, cortex, DRG, and
optic nerve (Fig. 5a). Hence, a MED25 mutation could
potentially affect the central nervous system. The absence
of central nervous clinical findings like ataxia or impair-
ment of the optic nerve in the CR-P patients points to
differences in molecular pathways between PNS and CNS,
may be because central axons are myelinated by oligoden-
drocytes. In this context it is of interest that a patient with
partial trisomy 19q including the MED25 gene among
several others had severe central nervous impairment [56].
Clinical and electrophysiological re-examination revealed,
however, no impairment at all of the peripheral nervous
system. This increased gene dosage for MED25 is in
heterozygous state thus supporting the assumption of an
autosomal recessive mode of inheritance for CMT2B2.
Our data demonstrate that functional effects of p.A335V
include loss-of-specific-function for SH3 ligand binding that
probably sequester MED25 to nonphysiological pathways.
Such potential altering of the availability of MED25 may
affecttranscriptional activationorregulationoftarget genes in
the peripheral nervous system. We further document that
Pmp22 expression correlates with Med25 expression levels
Neurogenetics (2009) 10:275–287 285in: (1) transgenic animals, both mice and rats, wherein the
Pmp22 expression is altered by effectively changing gene
copy number, (2) in animals wherein the Pmp22 expression is
altered by epigenetic means, and (3) in a nerve-crush/injury
paradigm.TheselatterfindingssuggestthatPMP22 may be at
least one of the genes downstream of MED25 that is
mediating the neuropathic effects of the p.A335V mutation.
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